Alcoholic liver disease

References

Key articles

Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.Full text  Abstract

Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.Full text  Abstract

Reference articles

1. Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019 Feb;23(1):39-50. Abstract

2. World Health Organization. Fact sheet: alcohol. Sep 2018 [internet publication].Full text

3. Julien J, Ayer T, Bethea ED, et al. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020 Jun;5(6):e316-e323.Full text  Abstract

4. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2018 national survey on drug use and health. 2019 [internet publication].Full text

5. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Alcohol facts and statistics. Jun 2021 [internet publication].Full text

6. Centers for Disease Control and Prevention. Alcohol and public health: alcohol-related disease impact (ARDI). Sept 2020 [internet publication].Full text

7. Grucza RA, Sher KJ, Kerr WC, et al. Trends in adult alcohol use and binge drinking in the early 21st-century United States: a meta-analysis of 6 national survey series. Alcohol Clin Exp Res. 2018 Oct;42(10):1939-50. Abstract

8. Dang K, Hirode G, Singal AK, et al. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastroenterol. 2020 Jan;115(1):96-104. Abstract

9. Public Health England. Official statistics: Liver disease profiles: short statistical commentary, October 2018. Oct 2018 [internet publication].Full text

10. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010 Jul;29(4):437-45. Abstract

11. Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018 Feb;113(2):175-94.Full text  Abstract

12. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011 Nov;141(5):1572-85.Full text  Abstract

13. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009 Jul 28;15(28):3462-71.Full text  Abstract

14. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002 Mar;35(3):635-8.Full text  Abstract

15. Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010 Mar 11;340:c1240.Full text  Abstract

16. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992 Nov 15;136(10):1248-57. Abstract

17. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96. Abstract

18. Zhao YY, Xiao M, Zhang CL, et al. Associations between the tumor necrosis factor-α gene and interleukin-10 gene polymorphisms and risk of alcoholic liver disease: A meta-analysis. Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):428-39. Abstract

19. Wang X, Yan Z, Ye Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18408.Full text  Abstract

20. Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol. 2015 Jun;110(6):846-56. Abstract

21. Li Y, Zhou J. Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease. Exp Biol Med (Maywood). 2017 Jun;242(11):1117-25.Full text  Abstract

22. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. Hepatology. 1991 Oct;14(4 Pt 1):581-9. Abstract

23. Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol. 1993 Jul;88(7):1016-21. Abstract

24. Loft S, Olesen KL, Dossing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987 Dec;22(10):1251-6. Abstract

25. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Women and alcohol. Jun 2019 [internet publication].Full text

26. Seitz HK, Stickel F. Alcoholic liver disease in the elderly. Clin Geriatr Med. 2007 Nov;23(4):905-21. Abstract

27. National Institute on Alcohol Abuse and Alcoholism. Surveillance report 111: Liver cirrhosis mortality in the United States: national, state, and regional trends, 2000–2015. April 2018 [internet publication].Full text

28. Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2017. Natl Vital Stat Rep. 2019 Jun;68(9):1-77.Full text  Abstract

29. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020 Jan;71(1):306-33.Full text  Abstract

30. Buchsbaum DG, Buchanan RG, Centor RM, et al. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med. 1991 Nov 15;115(10):774-7. Abstract

31. Girela E, Villanueva E, Hernandez-Cueto C, et al. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol. 1994 May;29(3):337-43. Abstract

32. Aalto M, Alho H, Halme JT, et al. AUDIT and its abbreviated versions in detecting heavy and binge drinking in a general population survey. Drug Alcohol Depend. 2009 Jul 1;103(1-2):25-9. Abstract

33. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-81.Full text  Abstract

34. Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009 Jan 7;15(1):67-80.Full text  Abstract

35. Ahmed Z, Ahmed U, Walayat S, et al. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018;11:301-7.Full text  Abstract

36. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci. 1979 Nov;24(11):835-8. Abstract

37. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.Full text  Abstract

38. Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. BMJ. 2015 Aug 3;351:h3692.Full text  Abstract

39. Yersin B, Nicolet JF, Dercrey H, et al. Screening for excessive alcohol drinking: comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. 1995 Sep 25;155(17):1907-11. Abstract

40. Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol. 1995 Mar;30(2):171-6. Abstract

41. Lumeng L. New diagnostic markers of alcohol abuse. Hepatology. 1986 Jul-Aug;6(4):742-5. Abstract

42. Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019 Feb;70(2):273-83.Full text  Abstract

43. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015 Jan 22;1:CD010542.Full text  Abstract

44. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989 Sep 15;111(6):473-8. Abstract

45. Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996 Jun;110(6):1847-53. Abstract

46. Shawcross DL, Dunk AA, Jalan R, et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):146-52.Full text  Abstract

47. Bell H, Tallaksen CM, Try K, et al. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994 Oct;18(5):1103-8. Abstract

48. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2;137(1):1-10. Abstract

49. Marsano LS, Mendez C, Hill D, et al. Diagnosis and treatment of alcoholic liver disease and its complications. Alcohol Res Health. 2003;27(3):247-56.Full text  Abstract

50. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul;30(1):37-47. Abstract

51. US Preventive Services Task Force., Curry SJ, Krist AH, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018 Nov 13;320(18):1899-1909.Full text  Abstract

52. Hoeksema HL, de Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract. 1993 Sep;37(3):268-76. Abstract

53. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007 Sep;11(34):1-206.Full text  Abstract

54. Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.Full text  Abstract

55. Berry PA, Thomson SJ, Rahman TM, et al. Review article: towards a considered and ethical approach to organ support in critically-ill patients with cirrhosis. Aliment Pharmacol Ther. 2013 Jan;37(2):174-82.Full text  Abstract

56. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med. 1968 Mar;44(3):406-20. Abstract

57. Veldt BJ, Laine F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002 Jan;36(1):93-8. Abstract

58. Altamirano J, López-Pelayo H, Michelena J, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology. 2017 Dec;66(6):1842-53.Full text  Abstract

59. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.Full text  Abstract

60. Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med. 2006 Aug;119(8):e7. Abstract

61. Sall D, Wang J, Rashkin M, et al. Orlistat-induced fulminant hepatic failure. Clin Obes. 2014 Dec;4(6):342-7. Abstract

62. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis. 2005 Feb;9(1):135-49. Abstract

63. McCullough AJ, Tavill AS. Disordered energy and protein metabolism in liver disease. Semin Liver Dis. 1991 Nov;11(4):265-77. Abstract

64. McCullough AJ, Bugianesi E. Protein-calorie malnutrition and the etiology of cirrhosis. Am J Gastroenterol. 1997 May;92(5):734-8. Abstract

65. Vasco M, Paolillo R, Schiano C, et al. Compromised nutritional status in patients with end-stage liver disease: role of gut microbiota. Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):290-300.Full text  Abstract

66. Swart GR, Zillikens MC, van Vuure JK, et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ. 1989 Nov 11;299(6709):1202-3.Full text  Abstract

67. Verboeket-Van De Venne WP, Westerterp KR, Van Hoek B, et al. Habitual pattern of food intake in patients with liver disease. Clin Nutr. 1993 Oct;12(5):293-7. Abstract

68. Stickel F, Hoehn B, Schuppan D, et al. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther. 2003 Aug 15;18(4):357-73.Full text  Abstract

69. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005 Jul;3(7):705-13.Full text  Abstract

70. Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010 Dec;53(6):1117-22. Abstract

71. Antar R, Wong P, Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol. 2012 Jul;26(7):463-7. Abstract

72. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017 May 18;(5):CD001939.Full text  Abstract

73. Koretz RL. The evidence for the use of nutritional support in liver disease. Curr Opin Gastroenterol. 2014 Mar;30(2):208-14. Abstract

74. Ney M, Vandermeer B, van Zanten SJ, et al. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther. 2013 Apr;37(7):672-9.Full text  Abstract

75. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998 Nov;93(11):2022-36.Full text  Abstract

76. Barve A, Khan R, Marsano L, et al. Treatment of alcoholic liver disease. Ann Hepatol. 2008 Jan-Mar;7(1):5-15. Abstract

77. Louvet A, Thursz MR, Kim DJ, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo: a meta-analysis of individual data from controlled trials. Gastroenterology. 2018 Aug;155(2):458-68. Abstract

78. Pavlov CS, Varganova DL, Casazza G, et al. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev. 2019 Apr 9;(4):CD001511.Full text  Abstract

79. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 1989 May 1;110(9):685-90. Abstract

80. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. Abstract

81. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003 Dec;38(6):1363-9.Full text  Abstract

82. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.Full text  Abstract

83. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990 Aug 15;113(4):299-307. Abstract

84. Mathurin P. Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transpl. 2005 Nov;(11 suppl 2):S21-4.Full text  Abstract

85. Hmoud BS, Patel K, Bataller R, et al. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver Int. 2016 May;36(5):721-8. Abstract

86. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003 Apr;38(4):419-25. Abstract

87. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390-7.Full text  Abstract

88. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 Apr;57(4):1651-3.Full text  Abstract

89. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.Full text  Abstract

90. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006 Oct;55 Suppl 6:vi1-12.Full text  Abstract

91. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.Full text  Abstract

92. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Full text  Abstract

93. Wong CL, Holroyd-Leduc J, Thorpe KE, et al. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA. 2008 Mar 12;299(10):1166-78.Full text  Abstract

94. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-53. Abstract

95. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.Full text  Abstract

96. Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009 Apr;7(4):487-93. Abstract

97. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994 Nov;20(5):1115-20. Abstract

98. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996 Jul;91(7):1374-9. Abstract

99. Keeffe EB. Comorbidities of alcoholic liver disease that affect outcome of orthotopic liver transplantation. Liver Transpl Surg. 1997 May;3(3):251-7. Abstract

100. Gong A, Minuk GY. Predictors of alcohol relapse following liver transplantation for alcohol-induced liver failure. consideration of "A-D" selection criteria. Ann Transplant. 2018 Feb 20;23:129-35.Full text  Abstract

101. Obed A, Bashir A, Stern S, et al. Severe acute alcoholic hepatitis and liver transplant: a never-ending mournful story. Clin Mol Hepatol. 2018 Dec;24(4):358-66.Full text  Abstract

102. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005 Feb;41(2):353-8.Full text  Abstract

103. Marot A, Dubois M, Trépo E, et al. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One. 2018 Jan 11;13(1):e0190823.Full text  Abstract

104. Al-Saeedi M, Barout MH, Probst P, et al. Meta-analysis of patient survival and rate of alcohol relapse in liver-transplanted patients for acute alcoholic hepatitis. Langenbecks Arch Surg. 2018 Nov;403(7):825-36.Full text  Abstract

105. Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1650-6.Full text  Abstract

106. Thompson J, Jones N, Al-Khafaji A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl. 2018 Mar;24(3):380-93.Full text  Abstract

107. Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017 Apr;15(4):600-2. Abstract

108. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9.Full text  Abstract

109. Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015 Oct;149(4):958-70.e12.Full text  Abstract

110. Saunders JB, Latt N. Epidemiology of alcoholic liver disease. Baillieres Clin Gastroenterol. 1993 Sep;7(3):555-79. Abstract

111. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193-9. Abstract

112. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992 Feb 20;326(8):507-12.Full text  Abstract

113. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005 Aug;54(8):1174-9.Full text  Abstract

114. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009 Oct;50(4):1175-83. Abstract

115. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD002907.Full text  Abstract

116. Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007 Sep;102(9):2086-102. Abstract

117. Yang J, Guo Z, Wu Z, et al. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005443.Full text  Abstract

118. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21.Full text  Abstract

119. Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009 Apr;43(4):692-9. Abstract

120. Sagi SV, Mittal S, Kasturi KS, et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010 May;25(5):880-5. Abstract

121. Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):229-33.Full text  Abstract

122. Centers for Disease Control and Prevention. Adult immunization schedule. Recommendations for ages 19 years or older, United States, 2022. Feb 2022 [internet publication].Full text

123. Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am. 1995 Dec;24(4):1047-64. Abstract

Use of this content is subject to our disclaimer